Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0VFBIW
ADC Name
AMG-224
Synonyms
AMG224; AMG 224
   Click to Show/Hide
Organization
Amgen, Inc.
Drug Status
Phase 1
Indication
In total 1 Indication(s)
Multiple myeloma [ICD11:2A83]
Phase 1
Antibody Name
Anti-human BCMA IgG1 Anti-ody
  Antibody Info 
Antigen Name
Tumor necrosis factor receptor superfamily member 17 (TNFRSF17)
  Antigen Info 
Payload Name
Mertansine DM1
  Payload Info 
Therapeutic Target
Microtubule (MT)
  Target Info 
Linker Name
Noncleavable linker
  Linker Info 
Puchem SID
472418778 , 440234651
ChEBI ID
CHEMBL4594520
General Information of The Activity Data Related to This ADC
Identified from the Human Clinical Data
Click To Hide/Show 2 Activity Data Related to This Level
Standard Type NCT Number Clinical Status Clinical Trial Description
Objective Response Rate (ORR)  NCT02561962
Phase 1
A phase 1 first in human study evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of AMG 224 in subjects with relapsed or refractory multiple myeloma.
Undisclosed  NCT02561962
Phase 1
A phase 1 first in human study evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of AMG 224 in subjects with relapsed or refractory multiple myeloma.
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
Click To Hide/Show 2 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Objective Response Rate (ORR)
23.00% (heavily pretreated population of patients with R/R MM with a median of seven lines of prior therapy)
60.00% (in a phase 1 trial of GSK2857916)
Patients Enrolled
Relapsed or refractory (R/R) multiple myeloma (MM).
Administration Dosage
Every 3 weeks (Q3W) at prespecified doses of 30-300 mg in a 3+3 design.
Related Clinical Trial
NCT Number NCT02561962  Clinical Status Phase 1
Clinical Description A phase 1 first in human study evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of AMG 224 in subjects with relapsed or refractory multiple myeloma.
Primary Endpoint
AmG 224 was generally well tolerated up to 190 mg Q3W.
Other Endpoint
ORR=23.00% (95% CI,11.00-39.00%), including six responses in dose escalation and three responses in the dose expansion. Two (5.00%) patients were CR and 7 (18.00%) patients were PR.
Experiment 2 Reporting the Activity Date of This ADC [2]
Related Clinical Trial
NCT Number NCT02561962  Clinical Status Phase 1
Clinical Description A phase 1 first in human study evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of AMG 224 in subjects with relapsed or refractory multiple myeloma.
References
Ref 1 Phase 1 study of the anti-BCMA antibody-drug conjugate AMG 224 in patients with relapsed/refractory multiple myeloma. Leukemia. 2021 Jan;35(1):255-258.
Ref 2 A Phase 1 First in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 224 in Subjects With Relapsed or Refractory Multiple Myeloma, NCT02561962

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.